Finally, it is known that one of the main pharmacological effects of IFN-γ is the increase in NO production, which acts as an executing arm of IFN-γ, mediating its beneficial and adverse effects in CGD patients. This evidence concerns the gene IFNG and chronic granulomatous disease.